Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025British Journal of DermatologyOpen Access

Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (S EASI DE CHINA): initial two-week dosing, followed by two-week or four-week dosing

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJianzhong ZhangJSJonathan I. SilverbergJGJiawang Guo

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates rademikibart efficacy in adults with atopic dermatitis, indicating significant improvements in skin lesions and pruritus.

Key Points

  • Rademikibart Q2W led to a 29.0% improvement in skin lesions at Week 16, compared to 5.9% for placebo.
  • Stage 1 showed significant gains in EASI-75 for rademikibart Q2W at 58.6% vs 22.6% for placebo at Week 16.
  • Observational analysis across 330 patients with moderate-to-severe AD monitored over 52 weeks shows continued efficacy.
  • No serious treatment-related adverse events were noted, supporting the safety profile of rademikibart therapy.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68c23b08b210217d64783085https://doi.org/10.1093/bjd/ljaf347
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of stapokibart, an anti–IL-4Rα monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: An open-label, single-arm phase 1b/2a trial2025
  2. 2Efficacy and Predictors of Low-Dose Abrocitinib in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: A Prospective Study.2025
  3. 3Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial2025
  4. 4Efficacy and Safety of Pumecitinib Gel for Treating Mild-to-moderate Atopic Dermatitis: a Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase IIb Clinical Trial2025
  5. 5Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis2026